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S U M M A R Y
Objectives: To evaluate regimens using bacillus Calmette–Gue´rin (BCG) or recombinant BCG (rBCG)
overexpressing Ag85B for priming, followed by boosting with a modiﬁed vaccinia virus Ankara strain
(MVA) and/or adenovirus vector (AD) expressing an Ag85B–ESAT6 fusion protein.
Methods: Cellular and humoral immune responses were determined after subcutaneous vaccination,
which was employed to trigger systemic immunity against intravenous infection in a mouse model of
tuberculosis (TB). Bacterial loads and lung histology were evaluated.
Results: The relative IgG2a and IgG1 antibody levels indicated that the viral-vectored vaccines generated
a T-helper type 1 (Th1)-biased response after two doses of viral boost vaccinations. Boosting BCG-primed
mice with viral vaccines induced a Th1 immune response that included both CD4 and CD8 T-cells
generating antigen-speciﬁc interferon-gamma (IFN-g) and CD8 T cytotoxic activity. Only mice
vaccinated with two different viral boosters after BCG priming exhibited a signiﬁcant reduction in
bacterial burden in the lung after challenge. Histology examinations conﬁrmed the attenuation of lung
damage and more compact granulomas. After mycobacteria priming, boosting with AD85B-E6 followed
by MVA85B-E6 afforded better protection than the reverse order of administration of the viral vectors.
Conclusions: This study demonstrates the potential of multiple heterologous viral booster vaccines,
although the exact correlates of protection and optimal regimens should be further investigated for the
rational design of future vaccine strategies.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Contents lists available at SciVerse ScienceDirect
International Journal of Infectious Diseases
jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Approximately a third of the world’s population is believed to
have been infected with Mycobacterium tuberculosis, the causative
bacterial agent of tuberculosis (TB). In 2010, there were an
estimated 8.8 million incident cases of TB and almost 1.5 million
deaths from TB.1 Although this airborne infectious disease can be
treated with the directly observed treatment short-course (DOTS)
strategy, the cost of the protracted drug treatment may be difﬁcult
to afford in some parts of the world. In addition, the emergence of
drug-resistant M. tuberculosis has further increased the difﬁculties
of clinical treatment. Hence, effective implementation of
vaccination programs would represent the most cost-effective
way to curb the global TB epidemic.2* Corresponding author. Tel.: +86 431 8516 7790; fax: +86 431 8519 5516.
E-mail addresses: jiangcl@jlu.edu.cn (C. Jiang), chysx6@163.com (W. Kong).
1201-9712/$36.00 – see front matter  2012 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2012.07.008The only anti-TB vaccine currently licensed, Mycobacterium
bovis bacillus Calmette–Gue´rin (BCG), has been used in humans
worldwide since 1921, but its efﬁcacy is somewhat controversial.
Although BCG is effective in protecting from severe forms of
childhood TB, principally miliary disease and meningitis, it has
failed to prevent the adult pulmonary TB epidemic, with a wide
range of efﬁcacy (0 to 80%). A variety of BCG strains are used in
different geographical locations, and it is believed that protection
induced by BCG wanes within 10 to 15 years, along with
diminishing protective T-cell immunity.3 Unlike extracellular
bacterial infections which are effectively eliminated by
antibody-inducing vaccines, M. tuberculosis is an intracellular
pathogen that requires, at least in part, strong cellular immune
responses for protective immunity. Thus, there is an urgent need to
develop improved TB vaccines and effective vaccination strategies
that are capable of promoting long-term cellular immunity.
Since BCG revaccination does not provide enhanced protection
and can even be deleterious,4–6 a heterologous prime-boost
immunization strategy represents an ideal way to extendses. Published by Elsevier Ltd. All rights reserved.
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date, several types of TB vaccines, such as protein adjuvant
formulations10–12 and viral-based13–16 and plasmid DNA
vaccines,17 have been used as boosters, and some combinations
have achieved encouraging results. In particular, recombinant viral
vectors, especially adenovirus- and poxvirus-based TB vaccines,
which can induce both cellular and humoral responses with strong
immunogenicity and good safety records,18–21 are highly promis-
ing candidates. Furthermore, respiratory tract vaccination with
recombinant viral carriers has the potential to defend against this
mucosal infectious disease.22
BCG provides thousands of antigens and stimulates the immune
system for prolonged periods of time as a live-attenuated vaccine,
in contrast to subunit vaccines based on one or a limited number of
antigens. Accordingly, attempts have been made to genetically
modify BCG to improve its immunogenicity.23–25 Among the
mycobacterial organism-based candidates, recombinant BCG 30
(rBCG30), which expresses high levels of Ag85B, has demonstrated
improved immunogenicity and protective efﬁcacy over the
traditional BCG in animals and has already entered clinical trials
with a well-established safety proﬁle.26–28 Thus, a combination
vaccine comprised of an rBCG vaccine followed by subsequent
viral-vectored boosters is a logical approach for enhancing the
protective efﬁcacy against TB.
In our previous work, a recombinant bivalent poxvirus-based
vector, MVA85B-E6, and an adenovirus-based vector, AD85B-E6,
both of which express the fusion protein Ag85B–ESAT6, were
engineered and evaluated as standalone vaccines.29 In the current
study, we investigated whether these recombinant viral vaccines
could boost conventional BCG-induced immunity and provide
enhanced protection. Furthermore, we investigated their effects as
booster vaccines after priming with rBCG overexpressing Ag85B.
We show that the protective efﬁcacy of mycobacterial vaccine-
primed mice was not improved by one dose of either viral booster,
while two boosters afforded enhanced protection in the lungs.
Furthermore, only the rBCG-primed mice receiving AD85B-E6 and
subsequent MVA85B-E6 exhibited enhanced protection against
M. tuberculosis H37Rv challenge. This study provides support for
multiple viral boosting for mycobacterial vaccination and contrib-
utes to the future rational design of immunization strategies
against TB.
2. Materials and methods
2.1. Recombinant proteins and peptides
Ag85B, ESAT6, and TB10.4 were expressed and puriﬁed with the
Ni-NTA Puriﬁcation System (Invitrogen) under denaturing condi-
tions as recombinant C-terminal 6  His-tagged proteins, as
described previously.30 Based on CD4 and CD8 T-cell epitope
mapping, H-2d-restricted class I peptides (9-2 peptide, Ag85B:
70–78, MPVGGQSSF; 9-1 peptide, Ag85B: 144–152, IYAGSLSAL) and
class II peptides (18-1 peptide, Ag85B: 100–117, FLTSELPQWLSAN-
RAVKP; 18-2 peptide, Ag85B: 262–279, HSWEYWGAQLNAMKGDLQ;
20 peptide, ESAT6: 1–20, MTEQQWNFAGIEAA-ASAIQG) were
used.31–35 All proteins and peptides were diluted in phosphate-
buffered saline (PBS) at a ﬁnal concentration of 1 mg/ml and were
stored in aliquots at 20 8C until used.
2.2. Preparation of Mycobacterium
M. bovis BCG and M. tuberculosis H37Rv were cultured in Difco
Middlebrook 7H9 broth supplemented with 10% BBL Middlebrook
albumin–dextrose–catalase (ADC) enrichment (BD Pharmingen) at
37 8C. After 3–4 weeks, the bacteria were harvested, washed twice
with PBS, resuspended in PBS containing 10% glycerol, and storedin aliquots at 80 8C until used. rBCG overexpressing Ag85B of
M. tuberculosis was generated by electrotransformation of BCG
with a plasmid, pSMT3-85B, which carries a hygromycin resistance
marker for selection. The same procedure above was used to
handle rBCG except for additional selection with 50 mg/ml of
hygromycin. Bacterial titers expressed as colony-forming units
(CFU) were determined by plating 10-fold serial dilutions onto
Middlebrook 7H11 agar plates containing 0.5% glycerol and
oleic acid–albumin–dextrose–catalase (OADC) enrichment (BD
Pharmingen).
2.3. Characterization of rBCG
The expression and secretion of Ag85B from rBCG in culture
were veriﬁed by Tricine-sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (Tricine-SDS-PAGE) and Western blotting. BCG
and rBCG were seeded at 1  109 CFU and cultured at 37 8C for
3 weeks. The bacteria were harvested by centrifugation at 3000  g
for 10 min for determining the CFU, and then the culture
supernatants were obtained by passage through a 0.45 mm ﬁlter
to remove the bacteria. The culture ﬁltrate proteins were
precipitated using ice-cold acetone, and the concentrated proteins
equivalent to those secreted by 1  108 bacteria in culture were
separated by electrophoresis on a polyacrylamide gel. The bands in
the digitized image were analyzed by assigning optical density
(OD) values using Bandscan 5.0. Plasmid stability in rBCG was
evaluated by subculturing the strain (1:20) six consecutive times
for 3 weeks each in the absence of hygromycin. Ag85B-related
cellular immune responses induced by rBCG were veriﬁed by
performing interferon-gamma (IFN-g) enzyme-linked immuno-
spot (ELISPOT) assays with Ag85B or an irrelevant antigen TB10.4.
2.4. Tricine-SDS-PAGE and Western blotting
Standard Tricine-SDS-PAGE was performed using a 12%
polyacrylamide separation gel and 4% stacking gel. After semi-
dry transfer onto nitrocellulose membranes, Western blotting was
performed with rabbit anti-M. tuberculosis Ag85B polyclonal
antibody (Abcam). Alkaline phosphatase-conjugated goat anti-
rabbit IgG (Jackson Immunoresearch) was used as the secondary
antibody and staining was carried out with 5-bromo-4-chloro-3-
indolylphosphate (BCIP) and nitroblue tetrazolium (NBT)
solutions.
2.5. Recombinant viruses
Recombinant MVA85B-E6 and AD85B-E6 were prepared as
described previously29 and diluted in PBS for vaccinations.
2.6. Mice, vaccination, and mycobacterial infection
Speciﬁc pathogen-free female BALB/c (H-2d) mice (6–8 weeks
old) were used. Uninfected mice were kept in animal facilities
under speciﬁc pathogen-free conditions. Two sets of animal
experiments were carried out in this study, each with six groups
of mice (n = 12). In experiment 1, BCG (designated as ‘B’) was
diluted in PBS and administered subcutaneously at a dose of
1  106 CFU, while PBS alone as a control and viral boosters were
given subcutaneously at a dose of 2  107 plaque-forming units
(PFU) for MVA85B-E6 (designated as ‘M’) or 1  107 PFU for
AD85B-E6 (designated as ‘A’), as outlined in Figure 1. Humoral
responses were determined 1 week after the ﬁnal vaccination. Two
weeks after the ﬁnal vaccination, ﬁve mice in each group were
sacriﬁced for evaluation of cellular-mediated immune responses.
After an additional 2 weeks, the remaining mice were challenged
by the intravenous route with 5  105 CFU of M. tuberculosis in a
Figure 1. Schematic diagram of the experimental design. In experiment 1, mice
(12 per group) were vaccinated at the indicated times and sacriﬁced at 12 weeks
(n = 5) or 22 weeks (n = 5) after the ﬁrst vaccination. Four weeks after the last
vaccination, mice were challenged with M. tuberculosis by the intravenous route at a
dose of 5  105 CFU. BCG (1  106 CFU, B), MVA85B-E6 (2  107 PFU, M), AD85B-E6
(1  107 PFU, A), or PBS (naı¨ve) were given as indicated. Humoral responses were
determined 1 week after the ﬁnal vaccination, while colony-forming assays and
histological analyses were performed at the time of sacriﬁce. In experiment 2, the
same procedure was carried out except that rBCG was used for priming instead of BCG.
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was used for priming instead of BCG, with the same dose and
procedure mentioned above for experiment 1. Animal care and
handling was performed by authorized personnel. All procedures
were approved by the Wuhan University Institutional Animal Care
and Use Committee (IACUC).
2.7. Humoral responses
Antigen-speciﬁc antibodies were detected by standard ELISA
1 week after the ﬁnal vaccination. The ELISA plates were precoated
with Ag85B or ESAT6 (0.25 mg/well). Sera diluted 1:25 and
horseradish peroxidase (HRP)-conjugated secondary antibody
diluted 1:4000 (goat anti-mouse IgG, IgG1, IgG2a; Southern
Biotech) were used, and the enzyme reaction was developed with
3,3,5,5-tetramethylbenzidine (TMB) substrate for 10–15 min and
terminated by the addition of 2 M H2SO4. OD values were
determined with a microplate reader at a wavelength of 450 nm.
2.8. Isolation of whole splenocytes
Immunized mice (n = 5) were sacriﬁced at 12 weeks after the
ﬁrst vaccination. Spleens were removed aseptically and pooled
into complete RPMI 1640 medium supplemented with 10% fetal
bovine serum (FBS), 100 U of penicillin/ml, 100 mg of streptomy-
cin/ml, and 2 mM L-glutamine. After red blood cell lysis with ACK
lysis buffer (NH4Cl 0.15 M, KHCO3 10.0 mM, ethylenediaminete-
traacetic acid disodium (Na2-EDTA) 0.1 mM, pH 7.2–7.4), spleno-
cytes were ﬁltered and resuspended at 1  107 cells/ml.
2.9. IFN-g ELISPOT assays
IFN-g ELISPOT assays were performed as described previous-
ly.29 Brieﬂy, splenocytes were seeded into the 96-well PVDF
microplate (3  105 cells/well) precoated overnight with mouse
IFN-g antibody. Cells were then incubated with or without the
stimulator (ﬁnal concentrations of 5 mg/ml) for 40 h at 37 8C, and
spots were developed in accordance with the manufacturer’s
protocol (BD Biosciences). The results were expressed as the
number of spot-forming cells (SFC) per 106 splenocytes.
2.10. In vitro cytotoxicity assay
In vitro cytotoxicity was determined as described previously.29
Brieﬂy, P815 cells were loaded with the Ag85B-CD8 peptideMPVGGQSSF (5 mg/ml; 2 h at 37 8C) and then labeled with
different concentrations of the carboxyﬂuorescein succinimidyl
ester (CFSE) ﬂuorescent dye (5 mM for peptide-loaded, 0.5 mM for
unloaded) in RPMI 1640 medium without FBS for 10 min.36
CFSEhigh- and CFSElow-labeled cells were mixed together in a 1:1
ratio. Splenocytes (1  106 cells) were then incubated with the
P815 cells (5  104 peptide-loaded, 5  104 unloaded) for 6 h at
37 8C, after which the co-cultures were analyzed on a BD
FACSCalibur for assessment of the percentage of CFSE-labeled
P815 cells. Speciﬁc killing was calculated as follows: % killing =
[1  (peptide loaded cells/unloaded cells from immunized group) 
(peptide loaded cells/unloaded cells from naı¨ve group)]  100.
2.11. Bacterial colony formation assay
The mice were sacriﬁced 8 weeks after the challenge. The right
lungs and spleen were removed and homogenized in 0.5% Tween-
80–PBS, and the bacterial burden was determined by plating 10-
fold serial dilutions in triplicate onto 7H11 medium. Plates were
incubated inside semi-sealed plastic bags at 37 8C in 5% CO2 for 3–4
weeks. Colonies were counted, calculated, and presented as
log10CFU per organ.
2.12. Lung histology
The left lungs were ﬁxed in 10% neutral buffered formalin and
embedded in parafﬁn. Sections approximately 5 mm thick were
stained with hematoxylin and eosin (H&E) for histological
examination and with Ziehl–Neelsen stain for evaluation of
acid-fast bacilli. The histopathological parameters of interstitial
inﬂammation, edema, peribronchiolitis, perivasculitis, and granu-
loma formation were each semi-quantitatively scored as absent,
slight, moderate, marked, or strong, and noted as 0, 1, 2, 3, and 4,
respectively. The cumulative inﬂammation score was expressed as
the sum of the scores for each parameter, with the maximum being
20. Conﬂuent inﬂammatory inﬁltrate was quantiﬁed separately
and expressed as a percentage of the lung surface. The results were
recorded by a pathologist without knowledge of the experimental
groups.
2.13. Statistical analysis
The data were analyzed using one-way analysis of variance
(ANOVA). Differences between the groups were assessed for
statistical signiﬁcance by Tukey’s post-hoc test. The Mann–
Whitney U-test was employed for analysis of histological
evaluations. A p-value of <0.05 was considered signiﬁcant.
3. Results
3.1. Humoral responses after vaccination
The protective role of antibodies against intracellular pathogens
is controversial. Nevertheless, it is conceivable that antibodies can
affect the course of infection and impart beneﬁcial effects. The
generation of antigen-speciﬁc IgG2a antibody is known to be
associated with the T-helper type 1 (Th1) response, whereas that of
IgG1 is a T-helper type 2 (Th2)-associated antibody.37 Hence, the
relative ratio of IgG2a to IgG1 reﬂects the Th1/Th2 balance. In
experiment 1 (Figure 2), marginal antibody responses to Ag85B
were induced after a single BCG vaccination. While elevated
antibody responses were observed following administration of the
MVA85B-E6 booster (B + M), the effect of the AD85B-E6 booster
(B + A) given at the same time-point was imperceptible. As
expected, the strongest responses were observed in the groups
given two boosters (B + A + M and B + M + A), and the IgG2a/IgG1
Figure 2. Humoral responses to BCG priming and viral vaccine boosting. Sera of the mice (n = 12) were collected 1 week after the ﬁnal vaccination and analyzed individually at
1/25 dilution by ELISA for the presence of Ag85B-speciﬁc IgG, IgG1, and IgG2a. Absorbance values (measured at 450 nm) are shown, with the vertical solid lines in each panel
representing means. The IgG2a/IgG1 ratio was obtained by dividing the mean OD value of IgG2a by that of IgG1.
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the other groups. Due to the low immunogenicity and absence of
ESAT6 in BCG, antibody responses to ESAT6 were weaker than
those to Ag85B after booster vaccination. However, levels of IgG2a
antibody to ESAT6 were obviously elevated compared to those of
IgG1 antibodies in the B + A + M and B + M + A groups (data not
shown). Together, these data demonstrate that viral boosters could
improve the humoral responses induced by BCG, and two boosters
after BCG priming considerably enhanced the ratio of IgG2a to
IgG1, indicating a Th1-biased immune response.
3.2. IFN-g responses after vaccination
Cell-mediated immunity was assessed by the frequency of IFN-
g-producing splenocytes in a sensitive ELISPOT assay in
experiment 1. To determine the relative contribution of each T-
cell subset to IFN responses, dominant CD8 and CD4 T-cell epitopes
were employed. As shown in Figure 3, a single vaccination with
BCG generated only marginal Ag85B-speciﬁc IFN-g producing
cells. After boosting with MVA85B-E6 or AD85B-E6, Ag85B-speciﬁc
IFN-g-secreting cells were signiﬁcantly increased. While booster
vaccination of MVA85B-E6 generated more 18-1p-speciﬁc CD4 T-
cells, AD85B-E6 as booster induced remarkable levels of both CD8
and CD4 IFN-g-producing T-cells, especially 9-2p-speciﬁc CD8 T-
cells. The B + M and B + A groups also showed enhanced IFN-g
responses as compared to those induced by a single viral vectored
vaccine immunization (data not shown). When BCG-primed mice
received two doses of viral boosters, Ag85B-speciﬁc IFN-g-
producing cells were not obviously increased as compared withFigure 3. Frequency of IFN-g-producing splenocytes induced by heterologous prime-bo
antigens (Ag85B, ESAT6) or peptides (9-2p, 9-1p, 18-2p, 18-1p) at a ﬁnal concentration of
each peptide was derived are indicated in brackets. Data are presented as the mean  sta
group. Spontaneous IFN-g-producing cells considered as background were subtracted. SFCthose from the B + A and B + M groups. However, IFN-g-secreting
CD8 T-cells in the B + A + M and B + M + A groups reached higher
levels than those of CD4 T-cells. In the assay, spots produced by
splenocytes stimulated with CD4 T-cell restricted peptides (18-2p
and 18-1p) were larger than those produced by the CD8 T-cell
restricted peptides (9-2p and 9-1p), implying higher IFN-g
production capacity on a per cell basis. As mentioned above, the
low immunogenicity of ESAT6 resulted in much fewer ESAT6-
speciﬁc than Ag85B-speciﬁc T-cells in the boosted groups. In
general, the prime-boost strategy could signiﬁcantly augment the
antigen-speciﬁc IFN-g-producing cells, and the CD8 T-cell
response was well developed especially in the groups with
AD85B-E6 boosting.
3.3. CD8 cytotoxic T-lymphocyte (CTL) responses in vitro
To further investigate the T-cell effector function in experiment
1, we detected CD8 cytotoxic T-lymphocyte (CTL) responses that
may be important for controlling intracellular infection. We co-
cultured splenocytes with syngeneic target cells (P815) pulsed
with the dominant Ag85B-speciﬁc CD8 T-cell peptide MPVGGQSSF
(9-2p) at an optimal 10:1 effector:target cell ratio in all groups
(Figure 4). As expected, vaccination with BCG followed by
MVA85B-E6 boosting, as with the previous ﬁnding29 that neither
alone could trigger CD8 CTLs, did not show signiﬁcant killing.
However, priming with BCG signiﬁcantly augmented AD85B-E6-
induced cytotoxicity from 21.7  1.2% to 32.9  1.0%. Furthermore,
the strongest speciﬁc CTL activity was generated by the B + M + A
group (50.9  1.2%), and the enhancement was signiﬁcant comparedost vaccination. Mouse splenocytes (3  105 cells/well) were incubated with whole
 5 mg/ml. Epitope restriction by either CD4 or CD8 T cells and the antigen from which
ndard error of the mean of triplicate wells of pooled splenocytes from ﬁve mice in each
, spot forming cells; B, BCG; M, MVA85B-E6; A, AD85B-E6.
Figure 4. In vitro CD8 T-cell cytotoxicity assay. P815 cells pulsed with the Ag85B-
speciﬁc CD8 T-cell peptide MPVGGQSSF (9-2p) were used as target cells. Data are
presented as the mean  standard error of the mean of triplicate co-culture samples
from pooled splenocytes of ﬁve mice from each group. ***p < 0.001; ns, not statistically
signiﬁcant.
Figure 5. Immune protection by different vaccination strategies 8 weeks after
M. tuberculosis challenge. The mice were challenged with M. tuberculosis
intravenously 4 weeks after the last vaccination. Mice were sacriﬁced 8 weeks
later and the M. tuberculosis bacterial titers in infected lungs (A) and spleens
(B) were determined by colony enumeration assays. Data are presented as the mean
 standard error of the mean of triplicate plates from pooled tissues of ﬁve mice in
each group. ***p < 0.001; ns, not statistically signiﬁcant. The comparisons were made
with the BCG group.
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were weaker than those of the B + A and B + M + A groups, indicating
that the cytotoxicity may have decreased over time, since adminis-
tration of AD85B-E6 in the B + A + M group was 2 weeks earlier than
that in the B + A and B + M + A groups. In summary, these results
demonstrate that the cytolytic activity of AD85B-E6 could be
enhanced by BCG or B + M priming, but it was transient and declined
rapidly. BCG and MVA85B-E6 were unable to trigger CTL activity
when used alone, but they could enhance 9-2p-speciﬁc CD8 T
cytotoxic activity tested at 2 weeks after the last immunization of
AD85B-E6.
3.4. Immune protection against TB
In order to determine whether the viral booster improved prior
BCG-induced protection, we challenged BALB/c mice with 5  105
CFU of M. tuberculosis (H37Rv) intravenously 4 weeks after the last
vaccination (Figure 1). Eight weeks later, bacterial burdens in lungs
and spleens were determined. Compared with naı¨ve controls (PBS
group), a single dose of BCG decreased the CFU counts by 1.2 log in
the lungs (Figure 5A) and spleens (Figure 5B). Surprisingly,
MVA85B-E6, which previously provided a striking level of
protection in both organs,29 could not enhance that induced by
BCG, indicating that even a vaccine that is efﬁcient by itself may
not necessarily be an appropriate booster to improve protective
efﬁcacy. Similar CFU counts were found in the B + A group and the
BCG group, suggesting that a single dose of AD85B-E6 booster
could not improve protection either. However, in the lungs of BCG-
vaccinated mice boosted with M + A and A + M, signiﬁcant
reductions in the bacterial titer were recorded (0.3 log and
0.6 log, respectively) compared with non-boosted BCG-vaccinated
mice, though both groups conferred splenic protection equivalent to
that by BCG. It should be noted that a better protective effect of
0.3 log CFU reduction in the lungs was signiﬁcant for mice boosted
with A + M compared with M + A-boosted mice. These results
suggest that combining more than one viral vaccine may be an
effective way to enhance BCG-induced protection, and the outcome
may be inﬂuenced by the order in which these boosters are
administered.
3.5. Evaluation of pathological changes after M. tuberculosis
challenge
We further assessed the pathology in the lungs of mice post-
infection. Based on gross examination of the mouse anatomy,nearly normal lungs with few tubercles were observed in the
vaccinated groups as compared to the lungs with visible tubercles
from the naı¨ve control group (PBS). After staining with H&E, the
lungs in the PBS group exhibited about 40% multifocal granulo-
matous inﬁltration, which was characterized by numerous central
foamy macrophages with scattered inﬁltrates of inﬂammatory
cells (Figure 6, A and C). In BCG-vaccinated mice, less than 20%
granulomatous inﬂammation was observed (Figure 6, A and D).
Boosting BCG with AD85B-E6 resulted in diffuse inﬂammation
with vigorous lymphocytic inﬁltration (Figure 6F), whereas more
aggregated lymphocytes were noted in the B + M group (Figure 6E)
than in the B + A group. Lymphocytes were also frequently found in
the lungs of the B + M + A group, as with those in the B + A group;
however, they were more regulated and the inﬂammatory
inﬁltrate was signiﬁcantly less diffuse (Figure 6, A and H). The
lungs in the B + A + M group appeared nearly normal except for
distinct compact granulomas, which contained and were sur-
rounded by abundant lymphocytes. However, the histological
changes in the viral vaccine-boosted groups were not signiﬁcantly
improved as compared to those in the BCG group in a semi-
quantitative evaluation of the pathological response (Figure 6B).
3.6. Characterization of rBCG
We also constructed and characterized a batch of rBCG
expressing Ag85B, which is a promising TB candidate vaccine in
clinical development, in order to test the boost potential of viral
vaccines to this improved mycobacterial vaccine. It was generated
by electrotransformation of wild-type BCG, and the expression of
Ag85B was analyzed in the culture. rBCG expressed a relatively
higher level of Ag85B (35.8%) as compared with that of the
Figure 6. Histological evaluation in lungs of M. tuberculosis-infected mice. The percentages of conﬂuent inﬂammatory inﬁltration in the lung (A) and cumulative inﬂammation
scores (B) were determined. Data are presented as box plots, wherein median values are denoted by a horizontal line, the mean by ‘+’, interquartile range by boxes, and the
maximum and minimum values by whiskers for each group. (C)–(H) show representative histological appearances of the lung tissues stained with H&E (regimens are
indicated in brackets). *p < 0.05.
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and this led to substantially enhanced Ag85B secretion by rBCG as
compared to that by the same number of BCG (Figure 7B). When
subcultured six times over an 18-week period in the absence of
hygromycin, the cultures showed no decrease in Ag85B expression
(Figure 7C), suggesting that rBCG could maintain overexpression of
Ag85B without selective pressure. To determine whether the
enhanced Ag85B secretion could improve the immunogenicity of
Ag85B, mice were injected subcutaneously at a dose of 1  106 CFU
BCG or rBCG. As expected, rBCG induced signiﬁcantly more Ag85B-
speciﬁc IFN-g-producing T-cells than did BCG (Figure 7D), while
responses to TB10.4, the other immunodominant antigen used as
an irrelevant stimulator, showed no difference in these two groups.
These results indicate that Ag85B overexpressing rBCG was
successfully constructed and that it could trigger increased
antigen-speciﬁc cell-mediated immune responses.
3.7. Effects of rBCG priming and viral boosting on protection against
TB challenge
The immune responses and protective efﬁcacy induced by rBCG
priming and viral vaccine boosting in experiment 2 were
evaluated. Immunization regimens here were the same as those
in experiment 1, except that rBCG was used for priming. As
observed in the BCG priming groups, two sequential viral boost
vaccinations enhanced antibody responses that favored the IgG2a
subclass and elevated the IgG2a/IgG1 ratio (Figure 8A). Results of
ELISPOT and CTL assays showed similar patterns between thegroups primed with rBCG and those with BCG (data not shown).
The bacterial burden was evaluated after challenge to determine
the protective efﬁcacy of the various immunization protocols, and
only mice in the rB + A + M group showed signiﬁcant CFU
reductions compared to a single dose of rBCG-vaccinated mice
in both lungs and spleens (0.4 log and 0.3 log, respectively). No
signiﬁcantly enhanced protective effect over that induced by rBCG
was observed for either organ in the rB + M + A group (Figure 8, B
and C). As with the histological changes observed in experiment 1,
rBCG followed by sequential AD85B-E6 and MVA85B-E6 boosting,
led to compact granulomas with markedly increased lymphocytic
inﬁltration relative to that induced by rBCG alone, and fewer
diffuse lymphocytes were seen in the surrounding parenchyma as
compared with that induced by rB + M + A vaccination (Figure 8, D,
E and F).
4. Discussion
BCG is the only approved vaccine against TB. However, it
generates limited protection due to extensive attenuation in
culture, interference by environmental mycobacteria, and early
clearance in some populations.38 Furthermore, the protection
afforded by this vaccine declines over time. Thus, there is an urgent
need to develop new anti-TB vaccination strategies. Since
continuous antigen exposure provided by a live bacterial vaccine
seems necessary for the maintenance of protection against TB, and
the booster should be non-mycobacterial organism-based, a
heterologous prime-boost immunization strategy was adopted
Figure 7. Analysis of rBCG. Culture ﬁltrate proteins of BCG and rBCG were analyzed
by Tricine-SDS-PAGE (A) and Western blot using a rabbit anti-M. tuberculosis Ag85B
polyclonal antibody (B and C). (A) and (B): lane 1, culture ﬁltrates from BCG; lane 2,
culture ﬁltrates from rBCG; lane M, molecular weight standard. (C) Plasmid stability
in rBCG was evaluated in the absence of hygromycin; lanes 1–6, culture ﬁltrates
from equivalent CFU of rBCG of the ﬁrst to the sixth passage; lane M, molecular
weight standard. (D) ELISPOT assays were performed with splenocytes from mice in
two independent experiments. Mice receiving a single dose of PBS, BCG, or rBCG
were sacriﬁced 4 weeks later. Representative wells (3  105 cells/well) in each
group are shown. Ag85B and TB10.4 were used at a concentration of 5 mg/ml, and
the negative control consisted of unstimulated splenocytes.
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protective efﬁcacy in mice vaccinated with BCG or rBCG priming
followed by boosting with viral-vectored vaccines.
During the past few years, viral vectors have been extensively
developed as vaccine platforms.39 Unlike DNA-based and protein-
based vaccines, viral vectors with their intense adjuvant activity
are effective at carrying and delivering antigen-encoding gene(s) to
trigger strong immune responses,40,41 especially cell-mediated
immune responses, which play a key role in eliminating
M. tuberculosis as an intracellular pathogen.42 Replication-deﬁcient
adenovirus and poxvirus vectors with good safety records have
been developed in the ﬁeld of TB vaccines.22 In fact, we previously
engineered the MVA85B-E6 vaccine, which showed a comparable
protective effect to that of BCG, while AD85B-E6 demonstrated no
protective efﬁcacy despite generating apparently high cell-
mediated immune responses.29 Those two vaccines were both
constructed to express Ag85B and ESAT6 as a fusion protein for
several reasons. First, the two antigens have been demonstrated to
be potent T-cell immunogens and contribute to protectiveimmunity. Second, since ESAT6 is absent in BCG, the introduction
of ESAT6 could broaden the range of epitopes available to
overcome major histocompatibility complex (MHC)-related
restrictions. Third, the fusion protein processing and presenting
may be more efﬁcient than a multiple component protein cocktail.
Furthermore, recent ﬁndings indicate that fusion antigens provide
improved immunogenicity and protection against TB, both as
protein-adjuvant formulation12 and as a gene product.43
The levels and IgG subclass distribution of serum antibodies can
give an indication of the nature of the vaccine-induced immune
responses. In this study, although a single viral booster generated
moderate effects on humoral responses, two sequential viral
booster vaccinations triggered enhanced antibody responses and
shifted the Th1/Th2 balance toward Th1 responses. The viral
vaccines induced predominantly the IgG2a isotype, which is quite
different from that triggered by protein-adjuvant formulations.
Even when formulated with an adjuvant that can induce cell-
mediated immunity, a protein antigen will still trigger mainly an
IgG1-speciﬁc response.44 This difference in favored antibody
subclasses reﬂects the differential nature of the immune responses
induced by virus and protein vaccines.
Due to distinct properties such as viral structure, entry,
replication and expression of foreign antigens, different viral
vector systems possess variable immune-stimulatory features.40,41
Recombinant adenoviruses generally induce robust CD8 T-cell
immunity and CTLs, whereas those responses stimulated by
modiﬁed vaccinia virus Ankara (MVA) vectors are relatively
weaker, as we and others have observed.29,39,45 Accordingly, they
also generate varying boosting effects on mycobacteria-triggered
immune activation. Hence, it is not surprising that the frequencies
of IFN-g-producing splenocytes and T cytotoxic activity were
substantially enhanced by a single AD85B-E6 boost, compared
with MVA85B-E6. Remarkably, the combination of MVA85B-E6
and AD85B-E6 further elevated the levels of IFN-g-secreting T-
cells, especially CD8 T-cells, suggesting a synergistic effect.
Intriguingly, speciﬁc cytotoxic T-cell activity in the B + A + M
group was lower than that of the B + A and B + M + A groups. This
may be explained by the kinetics of cytotoxicity triggered by
adenovirus, which is the pivotal inducer of CTLs. Although CTLs
provide potent defenses against intracellular pathogens, their lytic
machinery can be deleterious to self tissues.46 To balance the
beneﬁcial and detrimental effects, the host reduces the population
size of CTLs after destroying the targets in the contraction
phase.47,48 Therefore, the decreased CTLs may be due to the
earlier administration of AD85B-E6 in the B + A + M group
than that in the other groups. Furthermore, although BCG and
MVA85B-E6 did not induce signiﬁcant CTL activity when used
alone, their effects could synergize with that of the adenovirus
vector, thereby inducing the speciﬁc cytotoxicity to a higher level.
Deﬁning immune biomarkers that correlate with protection is
crucial to TB vaccine research and development. Although IFN-g is
a potent indicator of Th1 activity and has often been used as an
indicator of protective immunity,49 this correlation has recently
been questioned, at least in some studies.50–52 Appropriate subsets
of T-cells with multifunctional properties appear to be predictive
of protection in other studies,53–55 suggesting that the magnitude
and quality of T-cell responses would be useful in assessing
protection. Numerous studies have demonstrated that MVA
vectors engender more balanced CD4 and CD8 T-cell responses
than adenovirus vectors, which favor stronger CD8 T-cell
responses. In addition, MVA vectors generate accelerated peaks
of antigen expression and T-cell responses, followed by a quick
contraction. In contrast, adenovirus vectors generate persistent
antigen expression, with a delayed peak of T-cell responses and a
slow contraction.39,45,56 The differences in kinetics of antigen
clearance, subsets, and magnitude of T-cell responses will
Figure 8. Immune responses and protective efﬁcacy by combined viral boosting of rBCG. (A) Humoral responses of rBCG priming and viral vaccine boosting. Absorbance
values of speciﬁc anti-Ag85B IgG, IgG1, and IgG2a antibodies were determined by ELISA. Vertical solid lines indicate the means. Bacterial burdens were measured in the lungs
(B) and spleens (C) of mice. Data are presented as the mean  standard error of the mean of triplicates from ﬁve mice per group. ***p < 0.001; ns, not statistically signiﬁcant.
Comparisons were made with the BCG group. Representative histological images of lungs are shown for mice that were vaccinated with rB (D), rB + A + M (E), or rB + M + A (F).
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It becomes more complicated when two viral vaccines are
combined, and even the order of vaccination may inﬂuence
the outcome.59,60 In the present study, bacterial priming plus
AD85B-E6 boosting followed by MVA85B-E6 was shown to provide
better protection than that with MVA85B-E6 boosting followed by
AD85B-E6. Furthermore, the observation of more compact
granulomas with controlled lymphocyte recruitment suggests
that the effectiveness of this regimen may result from the
induction of T-cell responses with appropriate magnitude and
quality. Interestingly, the immune protection triggered by an
adenovirus vector followed by MVA vector has also been found to
be better than the reverse order of vaccination against malaria.59
Whether the order of administration of adenovirus and MVA
vaccines would be important in other vaccine ﬁelds and the precise
mechanisms underlying different regimens with varying protec-
tion levels will require further investigation.
rBCG was engineered as an alternate priming vaccine to BCG
for potential clinical application. Consistent with others
studies,61 rBCG did not afford better protection than BCG in
mice in our study, although it did show enhanced antigen
expression and immunogenicity. However, rBCG has been shown
to be highly protective in other animal models.23,26,27 Despite
the different levels of protection in various animal models, BCG
overexpressing Ag85B has entered clinical trials. Accordingly, we
investigated the efﬁcacy of viral boosters after rBCG priming.rB + A + M vaccination provided protection to both the lung and
the spleen, in contrast to rB + M + A vaccination. This ﬁnding was
somewhat different from the results observed in the B + A + M
and B + M + A groups and suggests that mycobacterial priming
with different strains can also inﬂuence the outcome. CD4 T-cell-
mediated heterologous immunity between mycobacteria and
poxviruses has been reported.62 Cross-reactivity that inﬂuences
the immune response to an unrelated pathogen may explain, at
least in part, why a single dose of MVA85B-E6 affording
signiﬁcant protective efﬁcacy could not boost that imparted
by the mycobacterial vaccine, and why distinct priming regi-
mens resulted in various levels of efﬁcacy. This hypothesis is
supported by recent ﬁndings that the immunogenicity of
MVA85A was reduced by co-administration with other
vaccines63 and AD85B-E6 induced serious pathology in the lung
surface with masses of tubercles when used alone,29 while we
found here that mycobacterial vaccine priming plus AD85B-E6
boosting resulted in a relatively normal anatomical appearance.
This may be due to the immune status primed by the
mycobacterial vaccine, probably inﬂuenced by regulatory
T-cells, which have been proven to be induced by mycobac-
teria64 and could be crucial players in balancing harmful tissue
damage and efﬁcient effector immunity.65 Thus, identifying how
the mycobacterial vaccine affects the host response to viruses
and the interactions between different types of vaccines is
important for the design of better vaccines.
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cells is important for the protective efﬁcacy against infection,66 i.e.,
the functional T-cells should be recruited and retained at the place
of infection. This idea is supported by recent studies showing that
only mucosal vaccination with viral vaccines can induce or
improve prior BCG-induced protection against aerosol chal-
lenge.15,20,67 Although the aerosol challenge more closely mimics
the natural route of TB infection, it is difﬁcult to carry out, and the
relatively imprecise dose limits its application. The intravenous
route of infection with a precise dose of bacteria is potentially
relevant for initial screening and comparative studies of multiple
vaccines given by parenteral immunization.68 The injected
bacteria infect the organs from the circulation, where they can
be encountered and eliminated by the functional T-cells induced
by the systemic route of vaccine administration. Of course, this
scenario is different from airway-invading bacteria, which would
require destruction by airway luminal T-cells induced by
respiratory mucosal immunization.69,70 The effectiveness of the
bacterial priming with two boosters of adenovirus and MVA
vectors here provides a foundation for further evaluation by
mucosal vaccination against aerosol challenge.
Much effort has been made to improve BCG induced protection.
However, the efﬁcacy ﬂuctuates with vaccine type and delivery,
antigen expression and duration, route of challenge, and animal
models. Combinations of different viral systems that can further
strengthen the cellular immunity, improve protection, and avoid
the limited efﬁcacy due to pre-existing immunity are increasingly
being studied for vaccination.60,71,72 The high plasticity of T-cell
responses also prompts the rational design of vaccination regi-
mens. Our study here characterized the immune responses and
protective efﬁcacy induced by mycobacteria as a priming vaccine
plus virus vectors for boosting. We conclude that AD85B-E6
followed by MVA85B-E6 boost vaccination can improve BCG- or
rBCG-induced protection. Our ﬁndings lend support to future
studies of mucosal viral vaccine immunization against aerosol
infection. Further work is also needed to identify more relevant
biomarkers for protective immunity and the precise mechanisms
of immunological memory formation. Nevertheless, this study
highlights the superior ability of multiple heterologous viral
booster vaccines and encourages the combined use of AD85A and
MVA85A, which will be evaluated in clinical trials in the near
future.
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